Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Core Viewpoint - Aclarion, Inc. has established an agreement with Source Healthcare to enhance the application of its Nociscan technology in addressing chronic low back pain, aiming to fill a significant gap in pain management solutions [1][2]. Group 1: Agreement and Strategic Expansion - The agreement with Source Healthcare aligns with Aclarion's strategy to expand the use of Nociscan, a non-invasive diagnostic tool for chronic low back pain [2]. - Source Healthcare, led by Dr. Timothy T. Davis, will integrate Nociscan into its multidisciplinary approach, generating real-world evidence to compare Nociscan with traditional anesthetic discography [2][3]. Group 2: Nociscan Technology and Benefits - Nociscan is a non-invasive alternative that objectively measures pain and structural integrity biomarkers in spinal discs, providing insights that traditional methods like MRI and discography do not offer [3][4]. - The technology has shown improved outcomes and lower costs in spinal fusion studies, and this collaboration aims to establish its efficacy in the broader pain management field [3][5]. - Approximately 266 million people globally suffer from chronic low back pain, highlighting the significant market potential for Nociscan [3]. Group 3: Clinical Validation and Growth Strategy - The partnership supports Aclarion's scalable growth strategy while building critical data assets necessary for payer and provider adoption of Nociscan [5]. - Nociscan's ability to provide clarity in diagnosing painful versus non-painful discs is expected to optimize treatment strategies for physicians [6].